4 hours ago
1
koto_feja/E+ via Getty Images
- Neurocrine Biosciences (NASDAQ:NBIX) reported one-year results from late-stage study of its experimental drug, Crenessity (crinecerfont), showing reductions in glucocorticoid dose and improvement in adults with congenital adrenal hyperplasia.
- The study showed patients were able to maintain lower, more natural doses of
English (US) ·